pp-256 Solution for injection/infusion
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Hematological disease, Inflammatory disease
Clinical stage: Phase 2
Modality: Peptide
Mechanism & Target: Pathway modulator, Immunomodulator
Route & form: SC injection / IV infusion
Differentiation: Properdin-targeting and VHH-based next-generation complement inhibitor for subQ dosing, currently in phase 2 studies in PNH and IgAN patients
Manufacturer #39671
A clinical-stage biopharmaceutical company focused on immunology / inflammatory diseases. Developing a biologic therapeutic targeting immunology / inflammatory diseases with global development focus. Pipeline positioned for regulatory advancement in key markets.
None